AMPK Activation by Peptides
How MOTS-c and a few other peptides are thought to switch on AMPK, the cell's energy sensor, and why the evidence so far comes almost entirely from mice.
Introduction
AMPK (AMP-activated protein kinase) is the cell's energy sensor. When ATP runs low, it shifts metabolism toward burning fuel. Nearly all peptide data on it comes from cell and mouse studies.
AMPK Basics
Function
| Role | Effect | Significance |
|---|---|---|
| Energy sensing | Detects low ATP | Metabolic switch |
| Glucose uptake | Increases | Improved utilization |
| Fat oxidation | Increases | More fat used for fuel |
| Mitochondrial biogenesis | Stimulates | Endurance capacity |
| Protein synthesis | May inhibit (mTOR) | Trade-off |
AMPK-Activating Peptides
MOTS-c
| Factor | Details |
|---|---|
| Origin | Mitochondrial DNA |
| AMPK activation | Indirect, via the folate cycle (cell studies) |
| Metabolic effects | Better insulin sensitivity (mice) |
| Exercise mimetic | Better running capacity (mice) |
| Human efficacy data | None credible |
As of October 2026, no peer-reviewed study has reported giving MOTS-c to people. Its analog CB4211 had one small fatty-liver trial (liver enzymes fell; liver fat fell on placebo too) before CohBar dropped it in 2023. WADA's 2026 Prohibited List names MOTS-c under S4.4.1 (non-Specified), banned at all times. See our MOTS-c profile.
Other Peptides
| Peptide | AMPK Effect | Mechanism |
|---|---|---|
| SS-31 | Indirect, unmeasured | Binds mitochondrial cardiolipin |
| Humanin | Unclear | Metabolic regulation |
| GH peptides | Variable | Indirect |
As of October 2026, SS-31 (elamipretide) is a prescription medicine, Forzinity, with FDA accelerated approval for Barth syndrome since September 2025. Its 12-patient trial and a dry macular degeneration trial missed their primary endpoints; we rate the evidence moderate (SS-31 profile).
AMPK vs. mTOR Balance
AMPK can switch off mTORC1, the driver of muscle protein synthesis (see the mTOR pathway).
The Trade-off
| State | AMPK | mTOR | Outcome |
|---|---|---|---|
| Energy deficit | High | Low | Catabolism, endurance |
| Energy surplus | Low | High | Anabolism, growth |
| Exercise | Transiently high | Post-exercise high | Adaptation |
| Fasting | High | Low | Autophagy |
Practical Applications
For Endurance Athletes
| Option | What's known |
|---|---|
| MOTS-c | Mouse data only; WADA-prohibited |
| Fasted training | Natural AMPK activation |
| Metformin | Prescription drug; no head-to-head data vs. MOTS-c |
Forum users report mixed MOTS-c results, from better endurance to nothing, plus frequent injection-site welts.
Exercise and AMPK
| Exercise Type | AMPK Activation |
|---|---|
| Endurance | High |
| HIIT | Moderate-High |
| Resistance | Low-Moderate |
Stay Updated on Peptide Research
Get weekly breakdowns of new studies, dosing insights, and community protocols. No spam, unsubscribe anytime.
References
- AMPK in skeletal muscle function and metabolism (The FASEB Journal, 2018)
- AMPK: guardian of metabolism and mitochondrial homeostasis (Nature Reviews Molecular Cell Biology, 2018)
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (Cell Metabolism, 2015; mouse and cell study)
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis (Nature Communications, 2021; mouse study with human exercise data)
- CohBar topline results of the Phase 1a/1b CB4211 study (SEC 8-K exhibit, 2021)
- CohBar quarterly report note on CB4211 formulation and merger (SEC filing, 2023)
- MOTS-c registry record review (Curo, vendor, 2026)
- World Anti-Doping Code 2026 Prohibited List (WADA, accessed October 2026)
- FDA grants accelerated approval to first treatment for Barth syndrome (FDA, 2025)
- Drug Trials Snapshots: Forzinity (FDA, 2025)
- ReCLAIM-2 Phase 2 trial of elamipretide in dry age-related macular degeneration (Ophthalmology Science, 2024)